Navigation Links
Sangamo BioSciences Announces Presentation at the Cowen and Company 31st Annual Health Care Conference
Date:3/1/2011

RICHMOND, Calif., March 1, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 10:15 am ET on Tuesday, March 8, 2011 at the Cowen and Company 31st Annual Health Care Conference which will be held in Boston.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and modification.  The most advanced ZFP Therapeutic® development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy and a Phase 2 trial in ALS. Sangamo also has a Phase 1/2 clinical trial and two ongoing Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS as well as a Phase 1 trial of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on Parkinson's disease, monogenic diseases, neuropathic pain and nerve regeneration.  Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function.  Sangamo is also developin
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections
2. Sangamo BioSciences Announces Presentation at the 13th Annual BIO CEO & Investor Conference
3. Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting
4. Sangamo BioSciences Announces Presentation at Lazard Capital Markets Healthcare Conference
5. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant Human Stem Cells
6. Sangamo BioSciences Receives Michael J. Fox Foundation Funding to Develop Novel Drug for the Treatment of Parkinsons Disease
7. Sangamo BioSciences Announces First Quarter 2010 Conference Call and Webcast
8. Sangamo BioSciences Announces Fourth Quarter and Full Year 2009 Conference Call and Webcast
9. Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium
10. Sangamo Announces Closing of Common Stock Offering
11. Sangamo BioSciences Announces Research Collaboration With UCLA in Human Stem Cells Selected to Receive Clinical Research Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... Mass., May 28, 2015  Shareholder rights law ... whether certain officers and directors of Eleven Biotherapeutics, ... Eleven Biotherapeutics is a clinical-stage biopharmaceutical company that ... therapeutics to treat eye diseases, primarily in ... View this press release on the law ...
(Date:5/28/2015)... 28, 2015   Eli Lilly and Company (NYSE: ... host a webcast on June 11 to discuss data from ... rheumatoid arthritis. Data from these two trials, RA-BEACON and RA-BUILD, will ... the EULAR Congress 2015 in Rome, Italy ... to11:00 a.m. Eastern Daylight Time. The live audio webcast can ...
(Date:5/28/2015)... ROCKLAND, Mass. , May 28, 2015 /PRNewswire/ ... a leading company for innovative and top-quality high-tech ... today announced a global collaboration agreement with the ... dedicated to advancing fertility science and helping couples ... Germany , a global market ...
Breaking Medicine Technology:Robbins Arroyo LLP Is Investigating the Officers and Directors of Eleven Biotherapeutics, Inc. (EBIO) on Behalf of Shareholders 2Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase III Data 2Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase III Data 3Merck KGaA, Darmstadt, Germany, as Pioneer in Assisted Reproductive Treatments, Takes Leading Role in Fertility Technologies, Announces a Global Collaboration Agreement with Genea Biomedx 2Merck KGaA, Darmstadt, Germany, as Pioneer in Assisted Reproductive Treatments, Takes Leading Role in Fertility Technologies, Announces a Global Collaboration Agreement with Genea Biomedx 3Merck KGaA, Darmstadt, Germany, as Pioneer in Assisted Reproductive Treatments, Takes Leading Role in Fertility Technologies, Announces a Global Collaboration Agreement with Genea Biomedx 4
... SuccessEHS, a nationally recognized, streamlined practice management and ... recently named by the Arkansas Regional Extension Center (REC) ... health care initiatives. Regional Extension ... endowed by the Office of the National Coordinator for ...
... 17, 2011 ORTHOCON, Inc., a developer of implantable products ... to bone, today announced the U.S. launch of its first ... The HEMA SORB Absorbable Bone Hemostat ... absorbable putty that is designed to rapidly stop bleeding when ...
Cached Medicine Technology:Arkansas REC Selects SuccessEHS as Preferred Vendor 2Arkansas REC Selects SuccessEHS as Preferred Vendor 3ORTHOCON® Announces U.S. Market Launch of HEMASORB® 2
(Date:5/28/2015)... Scotch Plains, NJ (PRWEB) May 28, 2015 ... Dr. Farhad Rafizadeh, specializes in delivering world-class results. ... of Plastic Surgery and a background in art, Dr. ... look. His unique approach to Plastic Surgery involves ... addition, his practice delivers a superior level of comfort ...
(Date:5/28/2015)... 2015 Medelis, Inc., a specialty oncology ... company in the role of president. , “ Bill Taaffe ... CRO industry,” said Larry Flanagan, Medelis’ CEO and co-founder. “He ... our next phase of growth.” , Taaffe joined ICON’s ... nine employees to over 4,500 employees, achieving 12 consecutive years ...
(Date:5/28/2015)... May 28, 2015 Boston Celtics Legend ... Beth, both Genesis Foundation Board of Directors members, will ... Celebrity Fishing Tournament June 4-7. For the past 34 ... benefitting The Genesis Foundation for children by bringing together ... , The 34th John Havlicek Celebrity Fishing Tournament will ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 Workers’ compensation costs ... typical state, a recent study by the Workers Compensation ... over a three-year period. , The WCRI study, CompScope™ ... which workers missed seven days or more of work with ... the average 2011 Michigan claim was 4 percent lower than ...
(Date:5/28/2015)... Dallas, TX (PRWEB) May 28, 2015 Ticket ... international friendly soccer match between Mexico and Argentina ... teams in the world will compete on the pitch at ... against one another in an international friendly on Tuesday, September ... the most talented nations in the world including some of ...
Breaking Medicine News(10 mins):Health News:"NJ Top Doc", Dr. Farhad Rafizadeh is Excited to Offer New Services at his Plastic Surgery Practice 2Health News:"NJ Top Doc", Dr. Farhad Rafizadeh is Excited to Offer New Services at his Plastic Surgery Practice 3Health News:Bill Taaffe, Former President and CEO of ICON Clinical Research-US, Joins Medelis, a Specialty Oncology CRO, in the Role of President 2Health News:The Genesis Foundation Prepares for Their Final Annual John Havlicek Celebrity Fishing Tournament 2Health News:Michigan Workers’ Compensation Costs Lower Than Most States, Says WCRI Study 2Health News:Mexico vs. Argentina Tickets at AT&T Stadium: Ticket Down Slashes Ticket Prices on Argentina vs. Mexico Presale Tickets at AT&T Stadium for 9/8/15 Friendly Match 2Health News:Mexico vs. Argentina Tickets at AT&T Stadium: Ticket Down Slashes Ticket Prices on Argentina vs. Mexico Presale Tickets at AT&T Stadium for 9/8/15 Friendly Match 3
... hormone treatment after surgery requiring heart bypass ,speeds ... defects, according to a clinical trial published in ... in the patients who underwent long and difficult ... critical illness, thyroid hormone concentrations plummet. Many experts ...
... weeks' gestation often ,have severe neurologic and developmental disabilities, ... New England,Journal of Medicine.The EPICure Study Group identified 308 ... or earlier in the UK and Ireland. Of these, ... lower scores on the Mental and Psychomotor Development Indexes ...
... Hopkins University research team has discovered a new ,family ... ,shedding new light on the abnormalities that give rise ... well as ,lymphoma, leukemia, prostate, ovarian, lung, and breast ... Burkitt's ,lymphoma is one of the three major types ...
... to some British researhers increasing doses of painkillers to ... shorten their lives.Some health professionals have criticized the practice, ... Hospice in London claim patients receiving higher doses of ... those who do not. , , ,In research published ...
... can be regenerated using stem cells from blood -- ... grow their own liver transplants using bone marrow. This adds ... as "master cells" because they can produce a variety of ... create custom-grown organ transplants. , , ,"The liver is an ...
... is one of the most difficult addiction to give up., , ... Canada it was found that medication called methoxsalen ( this is ... to give up smoking. , , ,Nicotine replacement, in the ... nicotine in blood up without smoking is currently used to help ...
Cached Medicine News:
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: